Lawsuits filed in New Jersey are part of hundreds of complaints against UnitedHealthcare, PBMs, and pharmaceutical giants over the price of insulin.

Signs at AMPAC Fine Chemicals' location in the Petersburg Industrial Park have already been changed to 'Novo Nordisk' in advance of the acquisition ...

Novo Nordisk’s takeover of Catalent and the Danish firm’s push to launch a new generation of drugs could boost the importance of GLP agonists in 2025, Barclays analysts said ...

Merck (NYSE:MRK) and Chinese biopharmaceutical company Hansoh Pharma (OTCPK:HNSPF) announced a global licensing deal on ...

particularly as a result of a major expansion of current supplies after Novo Nordisk was given a green light to complete its takeover of New Jersey drug manufacturer Catalent, Barclays' analysts said.

The state's fastest-growing such health care facility will debut 30,000 square feet of brand-new space to serve community ...

Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S ... Headquartered in ...

A lawyer for the employers predicts that discovery will show that collusion between drugmakers and PBMs had a significant ...

Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings ... in Somerset, New Jersey, the company ...

At least 29 patent suits were filed in the District of New Jersey in November ... Baughman & Stone represent Novo Nordisk in a suit against Apotex Inc. for alleged infringement of its patent ...

Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...